WallStreetZenWallStreetZen

NASDAQ: MAZE
Maze Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MAZE

Based on 6 analysts offering 12 month price targets for Maze Therapeutics Inc

Min Forecast
$34.00-21.59%
Avg Forecast
$44.67+3.01%
Max Forecast
$60.00+38.38%

Should I buy or sell MAZE stock?

Based on 6 analysts offering ratings for Maze Therapeutics Inc.

Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MAZE's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MAZE as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their MAZE stock forecasts and price targets.

MAZE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-16
lockedlocked$00.00+00.00%2025-12-04
lockedlocked$00.00+00.00%2025-12-03
lockedlocked$00.00+00.00%2025-11-07
lockedlocked$00.00+00.00%2025-09-29
Guggenheim
Top 9%
92
Strong BuyMaintains$34.00-21.59%2025-09-15Find out why

1 of 1

Forecast return on equity

Is MAZE forecast to generate an efficient return?

Company
-34.75%
Industry
355.57%
Market
202.3%
MAZE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MAZE forecast to generate an efficient return on assets?

Company
-31.24%
Industry
123.33%
MAZE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MAZE earnings per share forecast

What is MAZE's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$3.21
Avg 2 year Forecast
-$3.52
Avg 3 year Forecast
-$2.62

MAZE revenue forecast

What is MAZE's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$1.4M
Avg 2 year Forecast
$3.2M
Avg 3 year Forecast
$46.9M

MAZE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MAZE$43.36$44.67+3.01%Strong Buy
HRMY$36.84$44.50+20.79%Strong Buy
WVE$12.73$33.92+166.43%Strong Buy
DNTH$50.50$68.88+36.39%Strong Buy
OCUL$10.28$23.25+126.17%Strong Buy
View Top Biotech Stocks

Maze Therapeutics Stock Forecast FAQ

Is Maze Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: MAZE) stock is to Strong Buy MAZE stock.

Out of 6 analysts, 4 (66.67%) are recommending MAZE as a Strong Buy, 2 (33.33%) are recommending MAZE as a Buy, 0 (0%) are recommending MAZE as a Hold, 0 (0%) are recommending MAZE as a Sell, and 0 (0%) are recommending MAZE as a Strong Sell.

If you're new to stock investing, here's how to buy Maze Therapeutics stock.

What is MAZE's earnings growth forecast for 2026-2028?

(NASDAQ: MAZE) Maze Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.49%.

Maze Therapeutics's earnings in 2026 is -$101,458,000.On average, 11 Wall Street analysts forecast MAZE's earnings for 2026 to be -$154,550,030, with the lowest MAZE earnings forecast at -$190,514,503, and the highest MAZE earnings forecast at -$138,439,640. On average, 10 Wall Street analysts forecast MAZE's earnings for 2027 to be -$169,269,768, with the lowest MAZE earnings forecast at -$188,628,220, and the highest MAZE earnings forecast at -$136,923,878.

In 2028, MAZE is forecast to generate -$125,894,901 in earnings, with the lowest earnings forecast at -$210,792,036 and the highest earnings forecast at -$33,346,775.

What is MAZE's revenue growth forecast for 2026-2028?

(NASDAQ: MAZE) Maze Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.59%.

Maze Therapeutics's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast MAZE's revenue for 2026 to be $65,442,444, with the lowest MAZE revenue forecast at $0, and the highest MAZE revenue forecast at $606,304,994. On average, 10 Wall Street analysts forecast MAZE's revenue for 2027 to be $153,982,221, with the lowest MAZE revenue forecast at $0, and the highest MAZE revenue forecast at $636,620,244.

In 2028, MAZE is forecast to generate $2,259,159,776 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $8,635,515,420.

What is MAZE's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: MAZE) forecast ROA is -31.24%, which is lower than the forecast US Biotechnology industry average of 123.33%.

What is MAZE's Price Target?

According to 6 Wall Street analysts that have issued a 1 year MAZE price target, the average MAZE price target is $44.67, with the highest MAZE stock price forecast at $60.00 and the lowest MAZE stock price forecast at $34.00.

On average, Wall Street analysts predict that Maze Therapeutics's share price could reach $44.67 by Jan 16, 2027. The average Maze Therapeutics stock price prediction forecasts a potential upside of 3.01% from the current MAZE share price of $43.36.

What is MAZE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: MAZE) Maze Therapeutics's current Earnings Per Share (EPS) is -$4.65. On average, analysts forecast that MAZE's EPS will be -$3.21 for 2026, with the lowest EPS forecast at -$3.96, and the highest EPS forecast at -$2.88. On average, analysts forecast that MAZE's EPS will be -$3.52 for 2027, with the lowest EPS forecast at -$3.92, and the highest EPS forecast at -$2.85. In 2028, MAZE's EPS is forecast to hit -$2.62 (min: -$4.38, max: -$0.69).

What is MAZE's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: MAZE) forecast ROE is -34.75%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.